Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Queensland Health
Healthtrust
Cipla
Mallinckrodt
US Department of Justice
Citi
Farmers Insurance
Novartis

Generated: January 16, 2018

DrugPatentWatch Database Preview

DUETACT Drug Profile

« Back to Dashboard

Which patents cover Duetact, and when can generic versions of Duetact launch?

Duetact is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and thirty-two patent family members in thirty-six countries and fourteen supplementary protection certificates in eight countries.

The generic ingredient in DUETACT is glimepiride; pioglitazone hydrochloride. There are fourteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the glimepiride; pioglitazone hydrochloride profile page.

US Patents and Regulatory Information for DUETACT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa DUETACT glimepiride; pioglitazone hydrochloride TABLET;ORAL 021925-001 Jul 28, 2006 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Takeda Pharms Usa DUETACT glimepiride; pioglitazone hydrochloride TABLET;ORAL 021925-002 Jul 28, 2006 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Takeda Pharms Usa DUETACT glimepiride; pioglitazone hydrochloride TABLET;ORAL 021925-001 Jul 28, 2006 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Takeda Pharms Usa DUETACT glimepiride; pioglitazone hydrochloride TABLET;ORAL 021925-001 Jul 28, 2006 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa DUETACT glimepiride; pioglitazone hydrochloride TABLET;ORAL 021925-002 Jul 28, 2006 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa DUETACT glimepiride; pioglitazone hydrochloride TABLET;ORAL 021925-002 Jul 28, 2006 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for DUETACT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms Usa DUETACT glimepiride; pioglitazone hydrochloride TABLET;ORAL 021925-001 Jul 28, 2006 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa DUETACT glimepiride; pioglitazone hydrochloride TABLET;ORAL 021925-002 Jul 28, 2006 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa DUETACT glimepiride; pioglitazone hydrochloride TABLET;ORAL 021925-001 Jul 28, 2006 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa DUETACT glimepiride; pioglitazone hydrochloride TABLET;ORAL 021925-002 Jul 28, 2006 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa DUETACT glimepiride; pioglitazone hydrochloride TABLET;ORAL 021925-002 Jul 28, 2006 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa DUETACT glimepiride; pioglitazone hydrochloride TABLET;ORAL 021925-002 Jul 28, 2006 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa DUETACT glimepiride; pioglitazone hydrochloride TABLET;ORAL 021925-001 Jul 28, 2006 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa DUETACT glimepiride; pioglitazone hydrochloride TABLET;ORAL 021925-001 Jul 28, 2006 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa DUETACT glimepiride; pioglitazone hydrochloride TABLET;ORAL 021925-001 Jul 28, 2006 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa DUETACT glimepiride; pioglitazone hydrochloride TABLET;ORAL 021925-001 Jul 28, 2006 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for DUETACT
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 30 mg/2 mg and 30 mg/4 mg ➤ Subscribe 12/22/2009

Non-Orange Book US Patents for DUETACT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,599,923 Pharmaceutical composition ➤ Subscribe
6,121,294 Pharmaceutical composition ➤ Subscribe
6,156,773 Pharmaceutical composition ➤ Subscribe
6,211,205 Pharmaceutical composition ➤ Subscribe
5,952,356 Pharmaceutical composition ➤ Subscribe
6,214,848 Pharmaceutical composition ➤ Subscribe
6,211,206 Pharmaceutical composition ➤ Subscribe
6,133,295 Pharmaceutical composition ➤ Subscribe
6,169,100 Pharmaceutical composition ➤ Subscribe
6,169,099 Pharmaceutical composition ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for DUETACT

Supplementary Protection Certificates for DUETACT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0861666/01 Switzerland ➤ Subscribe FORMER REPRESENTATIVE: BOHEST AG, CH
606 Luxembourg ➤ Subscribe 91606, EXPIRES: 20210620
C 038/2006 Ireland ➤ Subscribe SPC 038/2006: 20070528, EXPIRES: 20210619
C026/2009 Ireland ➤ Subscribe SPC026/2009: 20101001, EXPIRES: 20210619
2007 00001 Denmark ➤ Subscribe
0258 Netherlands ➤ Subscribe 300258, 20160620, EXPIRES: 20210619
C/GB07/009 United Kingdom ➤ Subscribe SPC/GB07/009: 20070126
1174135/01 Switzerland ➤ Subscribe FORMER REPRESENTATIVE: BOHEST AG, CH
C0006 France ➤ Subscribe PRODUCT NAME: PIOGLITAZONE/METFORMINE ET LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/06/354/001 DU 20060728; REGISTRATION NO/DATE AT EEC: EU/1/06/354/001 DU 20060728
1 Finland ➤ Subscribe
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Fish and Richardson
Harvard Business School
Queensland Health
Deloitte
US Department of Justice
McKesson
Baxter
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot